MUVON Therapeutics
MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich, developing a therapeutic platform for skeletal muscle tissue regeneration based on autologous cells. Their mission is to provide safe, effective, and affordable treatments for debilitating diseases, initially focusing on stress urinary incontinence in women. They aim to develop personalized regenerative treatments to extend human health-span and address high unmet medical needs caused by muscle damage or degradation.
Industries
Nr. of Employees
small (1-50)
MUVON Therapeutics
Products
Autologous Muscle Precursor Cell Therapy for Female Stress Urinary Incontinence
A novel regenerative cell therapy for female stress urinary incontinence that utilizes a patient's own muscle precursor cells, isolated from a small muscle biopsy, expanded under GMP conditions, and injected into the sphincter muscle to regenerate tissue and restore strength.
Autologous Muscle Precursor Cell Therapy for Female Stress Urinary Incontinence
A novel regenerative cell therapy for female stress urinary incontinence that utilizes a patient's own muscle precursor cells, isolated from a small muscle biopsy, expanded under GMP conditions, and injected into the sphincter muscle to regenerate tissue and restore strength.
News & Updates
UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.
MUVON clears phase 2 interim milestone and announces participation in the 2025 J.P. Morgan Healthcare Conference.
MUVON CEO, Deana Mohr-Haralampieva, was recently featured in an exclusive interview with PharmaBoardroom.
MUVON ranked as a top 3 Biotech and overall 18th in 2024s TOP 100 Swiss Startups ranking.
Our latest paper has been published in Nature Reviews Bioengineering: Down to Business, discussing our approach for treating stress urinary incontinence.
MUVON was featured by Nature as a leader in innovative treatments for stress urinary incontinence.
UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.
MUVON clears phase 2 interim milestone and announces participation in the 2025 J.P. Morgan Healthcare Conference.
MUVON CEO, Deana Mohr-Haralampieva, was recently featured in an exclusive interview with PharmaBoardroom.
MUVON ranked as a top 3 Biotech and overall 18th in 2024s TOP 100 Swiss Startups ranking.
Our latest paper has been published in Nature Reviews Bioengineering: Down to Business, discussing our approach for treating stress urinary incontinence.
MUVON was featured by Nature as a leader in innovative treatments for stress urinary incontinence.